Fractional Resurfacing DeepFX and ActiveFX Featured at The American Society Of Aesthetic Plastic Surgery
DeepFX and ActiveFX were featured during this year’s annual meeting of The American Society of Aesthetic Plastic Surgery (ASAPS) in San Diego during the Cosmetic Medicine
course, chaired by Jeffrey Kenkel, MD of UTSW.
Dr. Kenkel has been using the fractional ActiveFX technology for more
than two years, and commented about Lumenis’ latest technological
advancement. “I’m excited about this new generation of CO2 devices because
I can offer my patients a single treatment that provides desired results
with manageable downtime,” Dr. Kenkel said.
Michael Kulick, MD, of San Francisco showcased DeepFX at the full-day
course. Dr. Kulick performed a live DeepFX treatment, answering audience
questions regarding pre- and post-treatment protocols, depth of
penetration, and optimal settings. He noted that his patient felt little to
no discomfort with the treatment, and had less post-operative side effects
than other fractional devices that were presented.
Deep FX, the latest in fractional treatment offered by Lumenis Inc.,
joins the already popular ActiveFX as a powerful way to treat wrinkles,
scars, skin tone and texture in a single treatment with minimum downtime.
ActiveFX targets the epidermal and papillary dermal layers of the skin
and is ideal for treating conditions that manifest in the upper layers of
the skin, including fine lines, dyschromia, and textural irregularities.
DeepFX, which was introduced in 2007, targets the deep dermal layers of the
skin, and provides exceptional results on deep wrinkles, scars, and
peri-oral rhytids.
“The UltraPulse Encore, is the only system with both DeepFX and
ActiveFX resurfacing options, providing physicians the most versatile CO2
laser in the industry” commented Dale Koop, Sr. Vice President and head of
Lumenis’ Strategic Aesthetic Business Unit. “Long known as the ‘gold
standard’ in the industry, the UltraPulse Encore is a shining example of
Lumenis’ commitment to the ongoing development and commercialization of
premium lasers to our physician customers”
Both the ActiveFX and DeepFX treatments gained widespread interest at
this ASAPS meeting. Jordan Farkas, MD, presented four talks that included
the dramatic histologic effects of ActiveFX and DeepFX. Dr. Farkas, who has
completed extensive research on fractional technology, was awarded with
this year’s Research Paper of the Year for his work. Kenneth Rothaus, MD,
FACS, also presented on Lumenis’ fractional technology, and featured
ActiveFX and DeepFX at the “Hot Topics in Cosmetic Surgery” discussion.
In the ASAPS meeting’s Scientific Session, “Fractional Resurfacing — A
Critical Assessment,” a report on the clinical outcomes and
histopathological results of ActiveFX and DeepFX, were presented by Dr.
Jeffrey Kenkel. Dr. Kenkel also noted that he likes to combine the Lumenis
fractional treatments. “Most patients have superficial and deep needs, so I
often combine ActiveFX and DeepFX,” he said. He presented photos of his
patients that received the treatments, and remarked on the exceptional
results that had been achieved.
Related Posts:
If you enjoyed this post, please consider to leave a comment or subscribe to the feed and get future articles delivered to your feed reader.
I am 69 years young and had deep fx treatment on the lower part of my face yesterday, from cheekbones to below chin. Not the eyes. I am amazed at how little discomfort I feel today. It is still somewhat red, of course, doesn’t hurt, doesn’t itch. Just a little stiff and warm and lightly swollen. I have smothered my face in aloevera (from Univeralifesciences) and lightly covered it in vaseline after. I will be just using the aloe from tomorrow. There is no oozing. Skin is dry. Basicxally: no big dealo. I am looking foreard to the end result.